Effect of Topiramate on Serum Etonogestrel Concentrations Among Contraceptive Implant Users.

ABSTRACT:

Objective

To evaluate topiramate and etonogestrel pharmacokinetic interactions in contraceptive implant users.

Methods

We conducted a prospective, noninferiority study with healthy women using etonogestrel implants continuously for 12-36 months. We measured baseline serum etonogestrel concentrations and then began a 6-week titrated topiramate regimen to standard migraine (100 mg/day) and epilepsy (400 mg/day) dosages. We repeated serum etonogestrel concentrations at 3 weeks (100 mg/day), 4 weeks (200 mg/day), and 6 weeks (400 mg/day) of topiramate therapy. We measured etonogestrel using a validated liquid chromatography-tandem, mass-spectrometry assay and tested for noninferiority (less than 30% decrease) in serum etonogestrel concentrations from baseline.

Results

We

SUBMITTER: Lazorwitz A 

PROVIDER: S-EPMC9140306 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature